0001127602-19-011993.txt : 20190319 0001127602-19-011993.hdr.sgml : 20190319 20190319083127 ACCESSION NUMBER: 0001127602-19-011993 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20190315 FILED AS OF DATE: 20190319 DATE AS OF CHANGE: 20190319 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: MAHON PAUL A CENTRAL INDEX KEY: 0001231589 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-26301 FILM NUMBER: 19690259 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: UNITED THERAPEUTICS Corp CENTRAL INDEX KEY: 0001082554 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 521984749 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1040 SPRING ST CITY: SILVER SPRING STATE: MD ZIP: 20910 BUSINESS PHONE: 3016089292 MAIL ADDRESS: STREET 1: 1040 SPRING ST CITY: SILVER SPRING STATE: MD ZIP: 20910 FORMER COMPANY: FORMER CONFORMED NAME: UNITED THERAPEUTICS CORP DATE OF NAME CHANGE: 19990324 4 1 form4.xml PRIMARY DOCUMENT X0306 4 2019-03-15 0001082554 UNITED THERAPEUTICS Corp UTHR 0001231589 MAHON PAUL A C/O UNITED THERAPEUTICS CORPORATION 1040 SPRING STREET SILVER SPRING MD 20910 1 EVP & General Counsel Common Stock 35823 D Stock Options 135.42 2019-03-15 4 A 0 150000 0 A 2023-03-15 2027-03-15 Common Stock 150000 150000 D Stock Options 117.76 2019-03-15 4 A 0 150000 0 A 2021-03-15 2027-03-15 Common Stock 150000 150000 D Includes 210 shares acquired on March 4, 2019, under the United Therapeutics Corporation Employee Stock Purchase Plan ("ESPP"). These stock options represent up-front equity grants covering four years of equity compensation for this named executive officer (2019 through 2022) and have been designed such that: (a) overall equity compensation expense on an annualized basis, and overall dilution, are both expected to be lower than if the Company had continued with the previous equity compensation program for four additional years; (b) the named executive officer will be incented to achieve the Company's business objectives over the four-year period; and (c) vesting is heavily weighted toward the end of the four-year period, in order to aid in retention over that timeframe. Exercise price is equal to 115% of the closing price for the Company's common stock on the date of grant. This award will cliff vest (100%) on March 15, 2023. These stock options will vest in equal one-third installments on March 15, 2021, 2022 and 2023. /s/ John S. Hess, Jr. under Power of Attorney 2019-03-18